Is Bevacizumab Effective in Inhibiting the Growth of Recurrent Pterygium?
نویسنده
چکیده
Objective: The objective of this selective EBM review is to determine whether or not Bevacizumab is an effective treatment in inhibiting the growth of recurrent pterygium. Study Design: Review of three published, English language randomized controlled trials published in 2010, 2012, and 2013. Data sources: Three randomized controlled trials measuring the efficacy of Bevacizumab to inhibit the growth of recurrent pterygium were found using PubMed and OVID databases. Outcome(s) Measured: The severity and progression of pterygium recurrence as well as corneal neovascularization were the main outcomes measured. Conjunctival injection, thickness, and size of the fibrovascular tissue were examined in subjects using ophthalmic evaluation including visual acuity testing, applanation tonometry, lit-lamp biomicroscopic examination, slit-lamp photography, indirect ophthalmoscopy, and corneal photographs. Results: In the study by Fallah, all groups failed, meaning fibrovascular tissue stretched onto the cornea. However, the mean duration for invasion of cornea in study group patients was significantly longer than for control group patients. The study by Lekhanont showed that Bevacizumab significantly transiently decreased the conjunctival injection. However, true recurrence was found in 62 of 80 patients with no statistically significant difference among the groups. In the study by Ozgurhan, pterygium recurrence was not noted in any patients in the study group, but was noted in 2 of 22 eyes in the control group. Moreover, corneal neovascularization was noted in 5 of 22 eyes in the control group but in none of the patients of the study group. Conclusion: The results of two of the randomized trials showed that Bevacizumab delays the recurrence of impending recurrent pterygium, but does not completely inhibit it. One of the randomized trials showed that Bevacizumab was an effective therapy for reducing recurrent pterygium and corneal neovascularization, but results were not statistically significant. Overall consistency was not provided and the data was inconclusive. All trials were limited due to small sample size and lack of follow-up studies.
منابع مشابه
Dose Assessment of Phosphorus-32 (32P) for the Treatment of Recurrent Pterygium
Introduction Pterygium is a wing-shaped, vascular, fleshy growth that originates from the conjunctiva and can spread into the corneal limbus and beyond. Beta irradiation after bare sclera surgery of primary pterygium is a simple, effective, and safe treatment, which reduces the risk of local recurrence. Materials and Methods Dosimetric components of strontium-90 (90Sr), phosphorous-32 (32P), an...
متن کاملSubconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium
Objective: to determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium. Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2ml/ 2.5mg). vascularity and thickness of Pterygium was gra...
متن کاملEffect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to ass...
متن کاملSubconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium
Vascular growth factors such as vascular endothelial growth factor (VEGF) have been detected in pterygium [12-15].There is marked elevation of VEGF in pterygia in comparison to normal conjunctival samples [12-15]. Although the pathogenesis of pterygia is still poorly understood, their formation and progression are known to depend on neovascularization. It has been postulated that the developmen...
متن کاملSubconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
PURPOSE We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia. METHODS The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before the injection and at 1 w...
متن کامل